Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pre-NDA Meetings Slated For Overhaul As Part Of New User Fee Cycle

Executive Summary

BOSTON - The renewal of the user fee program will produce significant changes in how FDA and application sponsors approach their presubmission meetings, Office of New Drugs Deputy Director Sandra Kweder said

You may also be interested in...



Postmarket Safety Managers Begin Oversight Roles In Drug Review Divisions

Associate directors for safety and safety-regulatory program managers have begun their postmarket drug safety oversight roles within FDA's Office of New Drugs' 17 drug review divisions

CDER Takes Steps To Meet First-Cycle Review Goals Of GRMP Guidance

ATLANTA - An agency-wide initiative to implement Good Review Management Principles at the Center for Drug Evaluation and Research should lead to more first-cycle reviews, CDER Associate Director of Regulatory Affairs Kim Colangelo said at a June 18 session of the Drug Information Association annual meeting

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Latest News
See All
UsernamePublicRestriction

Register

PS048891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel